// App-Quantinova.ai

: CHF5993 pMDI (extrafine Beclometasone Dipropionate:BDP, Formoterol Fumarate:FF, Glycopyrronium Bromide:GB) reduces Clinically Important Deteriorations (CID) in COPD: post-hoc analysis of TRILOGY study

Researchers

Presenter

  • Dave Singh

Principal Investigators

  • Alberto Papi

  • Stefano Vezzoli

  • Monica Spinola

  • Mario Scuri

  • Annamaria Muraro

  • Stefano Petruzzelli

  • Jorgen Vestbo

Medical Centers

  • University of Manchester, Manchester, United Kingdom

  • University of Ferrara, Ferrara, Italy

  • Chiesi Pharmaceuticals, Parma, Italy

Locations

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • beclometasone dipropionate

  • Glycopyrrolate

  • Formoterol

  • Seebri Breezhaler

  • beclometasone

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved